Vertex Pharmaceuticals (VRTX) Misses Q4 Earnings Estimates

Core Insights - Vertex Pharmaceuticals reported quarterly earnings of $3.98 per share, slightly missing the Zacks Consensus Estimate of $3.99 per share, and down from $4.20 per share a year ago, indicating an earnings surprise of -0.25% [1] - The company generated revenues of $2.91 billion for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 5.16%, and up from $2.52 billion year-over-year [2] - Vertex shares have increased approximately 16.5% since the beginning of the year, outperforming the S&P 500's gain of 2.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.07 on revenues of $2.72 billion, while for the current fiscal year, the estimate is $18.36 on revenues of $11.72 billion [7] - The estimate revisions trend for Vertex is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Vertex belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]